moneyheap
ILMN · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Illumina Inc (ILMN) stock moving?
Illumina reported Q3 2026 on Oct 29 with adjusted EPS of $1.44 beating the $1.36 estimate, while sales of $1.129B missed the $1.154B estimate. The company raised FY2026 adjusted EPS guidance to $5.40-$5.45 and sales guidance to $4.640B-$4.660B, but the stock fell from a $290.06 close on Oct 29 to $235.99 on Oct 30, an 18.6% drop on 5.39M shares against a typical volume near 2M. The price kept sliding to an $208.00 close on Nov 5 on 4.24M shares, then stabilized between about $208 and $221, closing at $214.91 on Nov 10 on lower volume of 1.36M. Post-earnings analyst actions are mixed: JPMorgan cut its target to $300 and Evercore to $275 while keeping positive ratings, Baird holds at a $236 target, Daiwa raised to $228, and Citigroup keeps a Sell with a $210 target near the current price, so the target range is wide ($210-$300). Management said 2027 is on track for high-single-digit revenue growth and at least a 25.5% operating margin as a starting point but is not issuing a formal 2027 forecast, and a royalty payment resumption is expected to help gross margins. Product and contract news (MRD early access program, Singapore SG-INSIGHT contract for about 450,000 residents) are positive but small relative to the earnings reset. The $1.0B commercial paper program set up in October adds funding flexibility.
News behind the analysis
- Illumina Exec Says 2027 Is On Track For High-Single-Digit Revenue Growth And At Least A 25.5% Operating Margin As A Starting Point, But It Is Not Giving 2027 ForecastAn executive said 2027 is tracking toward high-single-digit revenue growth and at least a 25.5% operating margin as a starting point. The company is not issuing a formal 2027 forecast.
- Daiwa Securities Adjusts Price Target on Illumina to $228 From $196Daiwa raised its Illumina price target from $196 to $228. The move lifts one of the more recent target increases after the Q3 report.
- Illumina Launches Early Access Program To Support Ultrasensitive Research Into Molecular Residual Disease And Tumor EvolutionIllumina launched an early access program for a new ultrasensitive duplex sequencing technology aimed at molecular residual disease research. The program is a research-stage step, not a commercial product launch.
- Illumina Expands Molecular Residual Disease (MRD) Research PortfolioThe company's early access program for ultrasensitive duplex sequencing extends its molecular residual disease research offering. Financial impact is not quantified in the item.
- Resumption of Illumina Royalty Payment AnnouncedAnalysts noted an upcoming resumption of a royalty payment to Illumina, which is expected to affect future gross margins. The source article is a GRAIL earnings piece, so the amount and timing are unclear.
- Baird Maintains Hold Rating and Raises Price Target for IlluminaBaird kept its Hold rating on Illumina and raised its price target to $236. The stock is trading slightly below that level.
- Reported Earlier, Illumina Wins Singapore SG-INSIGHT Sequencing Contract For About 450,000 Residents, Building On Phase II Delivery Of More Than 100,000 GenomesIllumina won a Singapore sequencing contract covering about 450,000 residents, building on Phase II delivery of more than 100,000 genomes. This is a concrete contract win that supports the precision medicine business.
- Citigroup Maintains Sell on Illumina, Raises Price Target to $210Citigroup kept its Sell rating and raised its price target from $113 to $210. The target sits close to the current share price.
- JP Morgan Maintains Overweight on Illumina, Lowers Price Target to $300JPMorgan kept its Overweight rating and cut its price target from $320 to $300 after the Q3 report. The cut reflects the post-earnings reset.
- Illumina Q3 Adj. EPS $1.44 Beats $1.36 Estimate, Sales $1.129B Miss $1.154B EstimateIllumina reported Q3 adjusted EPS of $1.44 versus a $1.36 estimate, but sales of $1.129B missed the $1.154B estimate. The company also raised FY2026 adjusted EPS guidance to $5.40-$5.45 and sales guidance to $4.640B-$4.660B.
About Illumina Inc
Illumina, based in San Diego, is the world's largest maker of next-generation DNA sequencing machines and the chemicals they run on. Labs, hospitals and drug developers use them for genetic research, cancer testing and diagnosing inherited diseases. Its NovaSeq X is its flagship high-output machine, and Illumina owns a very large share of the installed base worldwide.
How it makes money
Most revenue (very roughly three-quarters) comes from consumables, the single-use reagents and flow cells that labs buy over and over for each sequencing run. That gives Illumina a 'razor and blades' model: every machine it places keeps generating sales. The rest comes from selling the instruments and from service contracts. Clinical customers such as cancer and prenatal testing labs are growing, while research customers have been spending less. Company guidance for 2026 is about $4.65 billion in total revenue (approximate).
What usually moves ILMN
- Clinical sequencing demand (oncology, genetic disease testing)
- Academic and government research funding, e.g. NIH budgets
- NovaSeq X placements and consumables usage
- China trade restrictions and US–China policy
- Competition and pricing pressure in sequencing